vs

Side-by-side financial comparison of Borealis Foods Inc. (BRLS) and IMMUCELL CORP (ICCC). Click either name above to swap in a different company.

Borealis Foods Inc. is the larger business by last-quarter revenue ($7.1M vs $5.5M, roughly 1.3× IMMUCELL CORP). IMMUCELL CORP runs the higher net margin — -2.5% vs -53.2%, a 50.7% gap on every dollar of revenue. On growth, IMMUCELL CORP posted the faster year-over-year revenue change (-8.4% vs -12.0%). Over the past eight quarters, IMMUCELL CORP's revenue compounded faster (3.9% CAGR vs -2.4%).

Borealis Foods Inc is a food technology enterprise specializing in developing and producing high-quality plant-based protein products including plant-based meat alternatives. It mainly serves retail and food service customers across North America and Europe, focusing on delivering affordable, nutritious sustainable food options matching the taste of conventional animal-derived meat.

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

BRLS vs ICCC — Head-to-Head

Bigger by revenue
BRLS
BRLS
1.3× larger
BRLS
$7.1M
$5.5M
ICCC
Growing faster (revenue YoY)
ICCC
ICCC
+3.6% gap
ICCC
-8.4%
-12.0%
BRLS
Higher net margin
ICCC
ICCC
50.7% more per $
ICCC
-2.5%
-53.2%
BRLS
Faster 2-yr revenue CAGR
ICCC
ICCC
Annualised
ICCC
3.9%
-2.4%
BRLS

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
BRLS
BRLS
ICCC
ICCC
Revenue
$7.1M
$5.5M
Net Profit
$-3.8M
$-139.7K
Gross Margin
14.6%
42.9%
Operating Margin
-27.1%
0.4%
Net Margin
-53.2%
-2.5%
Revenue YoY
-12.0%
-8.4%
Net Profit YoY
21.8%
80.1%
EPS (diluted)
$-0.18
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BRLS
BRLS
ICCC
ICCC
Q3 25
$7.1M
$5.5M
Q2 25
$7.2M
$6.4M
Q1 25
$6.8M
$8.1M
Q4 24
$6.8M
$7.8M
Q3 24
$8.1M
$6.0M
Q2 24
$5.5M
$5.5M
Q1 24
$7.9M
$7.3M
Q4 23
$7.5M
$5.1M
Net Profit
BRLS
BRLS
ICCC
ICCC
Q3 25
$-3.8M
$-139.7K
Q2 25
$-4.6M
$501.9K
Q1 25
$-4.2M
$1.4M
Q4 24
$-5.8M
Q3 24
$-4.8M
$-701.7K
Q2 24
$-6.3M
$-1.5M
Q1 24
$-8.4M
$-437.9K
Q4 23
$-6.7M
Gross Margin
BRLS
BRLS
ICCC
ICCC
Q3 25
14.6%
42.9%
Q2 25
7.2%
43.7%
Q1 25
13.1%
41.6%
Q4 24
3.7%
36.5%
Q3 24
15.8%
26.3%
Q2 24
7.7%
22.5%
Q1 24
3.1%
31.6%
Q4 23
7.5%
24.7%
Operating Margin
BRLS
BRLS
ICCC
ICCC
Q3 25
-27.1%
0.4%
Q2 25
-46.7%
8.8%
Q1 25
-42.6%
13.9%
Q4 24
-68.4%
8.0%
Q3 24
-44.8%
-9.6%
Q2 24
-94.8%
-25.3%
Q1 24
-88.3%
-4.1%
Q4 23
-60.5%
-19.7%
Net Margin
BRLS
BRLS
ICCC
ICCC
Q3 25
-53.2%
-2.5%
Q2 25
-64.0%
7.8%
Q1 25
-61.2%
17.9%
Q4 24
-85.3%
Q3 24
-59.8%
-11.7%
Q2 24
-115.0%
-28.0%
Q1 24
-106.8%
-6.0%
Q4 23
-89.3%
EPS (diluted)
BRLS
BRLS
ICCC
ICCC
Q3 25
$-0.18
$-0.02
Q2 25
$0.21
$0.06
Q1 25
$-0.20
$0.16
Q4 24
$-0.82
$0.09
Q3 24
$-0.23
$-0.09
Q2 24
$0.29
$-0.20
Q1 24
$-0.49
$-0.06
Q4 23
$-0.63
$-0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BRLS
BRLS
ICCC
ICCC
Cash + ST InvestmentsLiquidity on hand
$3.9M
Total DebtLower is stronger
$9.5M
Stockholders' EquityBook value
$-12.9M
$29.8M
Total Assets
$56.3M
$45.7M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BRLS
BRLS
ICCC
ICCC
Q3 25
$3.9M
Q2 25
Q1 25
Q4 24
$3.8M
Q3 24
Q2 24
$1.3M
Q1 24
$960.3K
Q4 23
$978.7K
Total Debt
BRLS
BRLS
ICCC
ICCC
Q3 25
$9.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Q4 23
$10.5M
Stockholders' Equity
BRLS
BRLS
ICCC
ICCC
Q3 25
$-12.9M
$29.8M
Q2 25
$-9.2M
$29.9M
Q1 25
$-4.8M
$29.0M
Q4 24
$-695.9K
$27.5M
Q3 24
$5.1M
$26.4M
Q2 24
$9.9M
$23.5M
Q1 24
$16.2M
$24.6M
Q4 23
$-21.3M
$25.0M
Total Assets
BRLS
BRLS
ICCC
ICCC
Q3 25
$56.3M
$45.7M
Q2 25
$57.3M
$46.7M
Q1 25
$58.4M
$45.6M
Q4 24
$60.0M
$45.1M
Q3 24
$61.9M
$44.4M
Q2 24
$63.6M
$41.9M
Q1 24
$70.3M
$43.1M
Q4 23
$65.8M
$43.8M
Debt / Equity
BRLS
BRLS
ICCC
ICCC
Q3 25
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×
Q4 23
0.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BRLS
BRLS
ICCC
ICCC
Operating Cash FlowLast quarter
$-190.6K
$-1.2M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-32.3%
Capex IntensityCapex / Revenue
10.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BRLS
BRLS
ICCC
ICCC
Q3 25
$-190.6K
$-1.2M
Q2 25
$-2.2M
$1.6M
Q1 25
$-1.4M
$1.6M
Q4 24
$-819.4K
$-3.1K
Q3 24
$-3.3M
$-639.3K
Q2 24
$-4.2M
$581.8K
Q1 24
$-6.8M
$418.5K
Q4 23
$-1.9M
$-723.1K
Free Cash Flow
BRLS
BRLS
ICCC
ICCC
Q3 25
$-1.8M
Q2 25
$1.4M
Q1 25
$-1.4M
$1.2M
Q4 24
$-951.6K
$-199.3K
Q3 24
$-3.7M
$-727.7K
Q2 24
$-4.7M
$471.0K
Q1 24
$-7.3M
$348.1K
Q4 23
$-2.9M
$-804.4K
FCF Margin
BRLS
BRLS
ICCC
ICCC
Q3 25
-32.3%
Q2 25
22.4%
Q1 25
-20.3%
15.4%
Q4 24
-14.1%
-2.6%
Q3 24
-46.1%
-12.1%
Q2 24
-86.7%
8.6%
Q1 24
-92.7%
4.8%
Q4 23
-38.9%
-15.8%
Capex Intensity
BRLS
BRLS
ICCC
ICCC
Q3 25
10.8%
Q2 25
2.4%
Q1 25
0.2%
4.1%
Q4 24
2.0%
2.5%
Q3 24
5.6%
1.5%
Q2 24
9.4%
2.0%
Q1 24
7.0%
1.0%
Q4 23
12.7%
1.6%
Cash Conversion
BRLS
BRLS
ICCC
ICCC
Q3 25
Q2 25
3.19×
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons